Evolving Care of Heavily Treatment–Experienced Patients With HIV

In this call between colleagues, expert faculty discuss their approaches to assessing virologic failure in a patient with an extensive but incomplete treatment history, including recommendations on assessing adherence and determining which resistance tests are needed.

Princy N. Kumar, MD, FIDSA, MACP Brian Wood, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Pharmacists: 0.5 contact hours (0.05 CEUs) Released: February 22, 2021 Expired: February 21, 2022

In this call between colleagues, expert faculty discuss how they approach ART optimization in a virologically suppressed patient with HIV and multiclass resistance, including a discussion of relevant guidelines and data.

Roger Bedimo, MD, MS, FACP David A. Wohl, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Pharmacists: 0.5 contact hours (0.05 CEUs) Released: March 24, 2021 Expired: March 23, 2022

In this call between colleagues, expert faculty discuss how they select next-line ART for a heavily treatment–experienced patient with multiclass drug resistance experiencing virologic failure; discussion includes current and future options for treating patients with multiclass drug resistance.

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 19, 2021 Expired: April 18, 2022

Download this expert-authored slideset to review guidelines and key data on assessing virologic failure for patients with multiclass drug resistance.

Princy N. Kumar, MD, FIDSA, MACP Brian Wood, MD Released: February 22, 2021

Download this expert-authored slideset to review guidelines and key data on switching ART in a heavily-treatment experienced patient with HIV and multiclass drug resistance.

Roger Bedimo, MD, MS, FACP David A. Wohl, MD Released: March 24, 2021

Download this expert-authored slideset to review guidelines and key data on selecting next-line ART for a heavily-treatment experienced patient with multiclass drug resistance experiencing virologic failure.

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Released: April 19, 2021